1. Insco, Megan L, Abraham, Brian J, Dubbury, Sara J, Boutz, Paul L, Zon, Leonard I. 2023. Oncogenic CDK13 mutations impede nuclear RNA surveillance. In Science (New York, N.Y.), 380, eabn7625. doi:10.1126/science.abn7625. https://pubmed.ncbi.nlm.nih.gov/37079685/
2. Quereda, Victor, Bayle, Simon, Vena, Francesca, Roush, William R, Duckett, Derek R. 2019. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. In Cancer cell, 36, 545-558.e7. doi:10.1016/j.ccell.2019.09.004. https://pubmed.ncbi.nlm.nih.gov/31668947/
3. Zhang, Yong, Chen, Xiao-Nan, Zhang, Hong, Qu, Chang-Bao, Yang, Zhan. 2023. CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA. In Cell death and differentiation, 30, 2462-2476. doi:10.1038/s41418-023-01223-z. https://pubmed.ncbi.nlm.nih.gov/37845385/
4. Zhu, Tianyu, Li, Qian, Zhang, Zhe, Shen, Jianfeng, Jia, Renbing. 2024. ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner. In BMC biology, 22, 132. doi:10.1186/s12915-024-01927-9. https://pubmed.ncbi.nlm.nih.gov/38835016/
5. Jiang, Baishan, Gao, Yang, Che, Jianwei, Zhang, Tinghu, Gray, Nathanael S. 2021. Discovery and resistance mechanism of a selective CDK12 degrader. In Nature chemical biology, 17, 675-683. doi:10.1038/s41589-021-00765-y. https://pubmed.ncbi.nlm.nih.gov/33753926/
智鼠故事 
